Analysts expect that Theravance Biopharma Inc (NASDAQ:TBPH) will report earnings of ($1.15) per share for the current fiscal quarter, Zacks reports. Two analysts have provided estimates for Theravance Biopharma’s earnings. The lowest EPS estimate is ($1.16) and the highest is ($1.14). Theravance Biopharma reported earnings of ($1.36) per share in the same quarter last year, which would suggest a positive year over year growth rate of 15.4%. The firm is scheduled to announce its next earnings results on Monday, February 26th.
On average, analysts expect that Theravance Biopharma will report full-year earnings of ($4.84) per share for the current financial year, with EPS estimates ranging from ($5.01) to ($4.49). For the next fiscal year, analysts forecast that the business will report earnings of ($4.44) per share, with EPS estimates ranging from ($4.75) to ($4.17). Zacks Investment Research’s EPS calculations are an average based on a survey of analysts that follow Theravance Biopharma.
Theravance Biopharma (NASDAQ:TBPH) last issued its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($1.27) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.22) by ($0.05). Theravance Biopharma had a negative return on equity of 99.43% and a negative net margin of 1,604.87%.
Several institutional investors have recently modified their holdings of TBPH. QS Investors LLC purchased a new position in shares of Theravance Biopharma during the second quarter valued at about $100,000. Ameritas Investment Partners Inc. lifted its holdings in shares of Theravance Biopharma by 6.3% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 3,865 shares of the biopharmaceutical company’s stock valued at $153,000 after acquiring an additional 230 shares during the last quarter. Amalgamated Bank bought a new position in shares of Theravance Biopharma in the 2nd quarter valued at about $214,000. Moneta Group Investment Advisors LLC bought a new position in shares of Theravance Biopharma in the 3rd quarter valued at about $299,000. Finally, SG Americas Securities LLC lifted its holdings in shares of Theravance Biopharma by 52.8% in the 3rd quarter. SG Americas Securities LLC now owns 9,061 shares of the biopharmaceutical company’s stock valued at $310,000 after acquiring an additional 3,130 shares during the last quarter. Hedge funds and other institutional investors own 86.04% of the company’s stock.
Shares of Theravance Biopharma (TBPH) traded up $4.86 during mid-day trading on Wednesday, reaching $29.30. The company’s stock had a trading volume of 322,458 shares, compared to its average volume of 202,911. Theravance Biopharma has a 1-year low of $22.90 and a 1-year high of $43.44. The company has a debt-to-equity ratio of 1.21, a current ratio of 7.53 and a quick ratio of 7.21. The stock has a market cap of $1,264.40, a price-to-earnings ratio of -5.69 and a beta of 1.88.
WARNING: This news story was first reported by American Banking News and is the property of of American Banking News. If you are reading this news story on another site, it was illegally copied and reposted in violation of US and international trademark & copyright laws. The correct version of this news story can be viewed at https://www.americanbankingnews.com/2018/02/07/theravance-biopharma-inc-tbph-expected-to-announce-earnings-of-1-15-per-share.html.
Theravance Biopharma Company Profile
Theravance Biopharma, Inc is a biopharmaceutical company. The Company is engaged in creating medicines for patients suffering from serious illness. The Company operates in the segment of discovery (research), development and commercialization of human therapeutics. The Company’s pipeline of internally discovered product candidates includes medicines to address the unmet needs of patients being treated for serious conditions primarily in the acute care setting.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Theravance Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theravance Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.